BIODESIX INC(BDSX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

BIODESIX INC (BDSX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDSX at 35.0/100 on a 32-signal composite quality model, placing it at rank #2,325 of 2,961 stocks — the bottom half of the AI-ranked universe. BDSX scores in the top quartile across revenue growth (89.0). Areas of concern include balance sheet strength (7.7) and free cash flow (13.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIODESIX INC reports quarterly revenue of $26.9M, net income of $-7.3M, an operating margin of -20.1%. Top institutional holders of BDSX by reported 13-F value include AIGH Capital Management, Soleus Capital Management, L.P., Telemark Asset Management, based on the most recent SEC filings. BDSX trades on the Nasdaq exchange and files with the SEC under CIK 1439725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDSX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIODESIX INC directly from SEC EDGAR.